Niagen Bioscience (NAGE) investor relations material

Business and research

• Four business lines span consumer supplements and skincare, ingredient supply, Niagen Plus IV/injections, and pharmaceutical development.

• Management cited 52 peer-reviewed clinical studies on NR and 30 more underway; it estimated the global NAD supplement market at $3B, versus $10M 8–10 years earlier.

• Management positioned NR as its preferred NAD precursor and cited a Norway study finding NR 2.3x more effective than NMN at elevating NAD.

Consumer products and marketing

• Tru Niagen is a ~$100M supplement, sold mainly through Amazon and its website, with Watsons in parts of Asia and limited U.S. retail; Nestlé and Life Extension also sell NR products.

• Direct website sales grew more than 30% last year, while sales were flat this year amid lower-priced competitors; management expects supplement growth to resume as awareness and product range expand.

• NanoCloud skincare launched after studies indicated topical NR penetrates skin and raises NAD in skin cells; management expects a major skincare partner to launch a widely distributed product in Q1 next year.

• Marketing investment has increased and could remain elevated for one or two quarters; a Kelly Slater campaign is intended to build brand awareness.

Ingredient and delivery businesses

• Ingredient customers include Nestlé, H&H, and Life Extension; a Goli NR gummy was expected to launch shortly.

• Nicotinamide riboside malate is a lower-cost ingredient intended for broader supply to supplement brands; whether to launch it under Tru Niagen remained under review.

• Niagen Plus offers pharmaceutical-grade NR through clinics and at-home injection kits; management described the kits as selling, while its plans for aggressive investment in the channel remained undecided.